469 related articles for article (PubMed ID: 12672310)
1. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
Anker SD; Negassa A; Coats AJ; Afzal R; Poole-Wilson PA; Cohn JN; Yusuf S
Lancet; 2003 Mar; 361(9363):1077-83. PubMed ID: 12672310
[TBL] [Abstract][Full Text] [Related]
2. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Cintron G; Johnson G; Francis G; Cobb F; Cohn JN
Circulation; 1993 Jun; 87(6 Suppl):VI17-23. PubMed ID: 8500235
[TBL] [Abstract][Full Text] [Related]
4. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
[TBL] [Abstract][Full Text] [Related]
5. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
Johnson G; Carson P; Francis GS; Cohn JN
Circulation; 1993 Jun; 87(6 Suppl):VI32-9. PubMed ID: 8500237
[TBL] [Abstract][Full Text] [Related]
6. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Ziesche S; Cobb FR; Cohn JN; Johnson G; Tristani F
Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
[TBL] [Abstract][Full Text] [Related]
7. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
Cohn JN; Johnson G; Ziesche S; Cobb F; Francis G; Tristani F; Smith R; Dunkman WB; Loeb H; Wong M
N Engl J Med; 1991 Aug; 325(5):303-10. PubMed ID: 2057035
[TBL] [Abstract][Full Text] [Related]
8. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
Carson P; Johnson G; Fletcher R; Cohn J
J Am Coll Cardiol; 1996 Mar; 27(3):642-9. PubMed ID: 8606276
[TBL] [Abstract][Full Text] [Related]
9. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
Ahmed A
J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
[TBL] [Abstract][Full Text] [Related]
10. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group.
Fletcher RD; Cintron GB; Johnson G; Orndorff J; Carson P; Cohn JN
Circulation; 1993 Jun; 87(6 Suppl):VI49-55. PubMed ID: 8500239
[TBL] [Abstract][Full Text] [Related]
11. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial.
Funck-Brentano C; van Veldhuisen DJ; van de Ven LL; Follath F; Goulder M; Willenheimer R;
Eur J Heart Fail; 2011 Jul; 13(7):765-72. PubMed ID: 21551161
[TBL] [Abstract][Full Text] [Related]
12. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
[TBL] [Abstract][Full Text] [Related]
13. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
Carson P; Ziesche S; Johnson G; Cohn JN
J Card Fail; 1999 Sep; 5(3):178-87. PubMed ID: 10496190
[TBL] [Abstract][Full Text] [Related]
14. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
[TBL] [Abstract][Full Text] [Related]
15. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
Parker AB; Yusuf S; Naylor CD
Am Heart J; 2002 Dec; 144(6):941-7. PubMed ID: 12486418
[TBL] [Abstract][Full Text] [Related]
16. [The role of ACE inhibitors in heart failure. Lessons of CONSENSUS, SOLVD and V-HeFTII].
Dessì-Fulgheri P; Paci MV; Rappelli A
Ann Ital Med Int; 1994 Oct; 9 Suppl():16S-18S. PubMed ID: 7857751
[TBL] [Abstract][Full Text] [Related]
17. [Value of ACE inhibitors in heart failure (clinical aspects)].
Riegger AJ
Z Kardiol; 1992; 81 Suppl 4():93-6. PubMed ID: 1290309
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
Goldman S; Johnson G; Cohn JN; Cintron G; Smith R; Francis G
Circulation; 1993 Jun; 87(6 Suppl):VI24-31. PubMed ID: 8500236
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
[TBL] [Abstract][Full Text] [Related]
20. Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
Cohn JN
Drugs; 1994; 47 Suppl 4():47-57; discussion 57-8. PubMed ID: 7523062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
